Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
24 avr. 2024 10h00 HE
|
Autolus Therapeutics plc
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL at ASCO
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
23 avr. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
02 avr. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics announces acceptance of MAA by the EMA for obe-cel for patients with B-ALL
Autolus Therapeutics Announces Changes to its Board of Directors
01 avr. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Announces Changes to its Board of Directors
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
14 mars 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
12 mars 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
Autolus Therapeutics announces publication in Blood Cancer Journal
11 mars 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics announces publication in Blood Cancer Journal
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
29 févr. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
Autolus Therapeutics announces publication in Nature Communications
22 févr. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics announces publication in Nature Communications
Autolus Announces Pricing of Underwritten Offering
08 févr. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Announces Pricing of Underwritten Offering